NCT05156203View on ClinicalTrials.gov

Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 19, 2021

Primary Completion Date

January 31, 2027

Study Completion Date

December 31, 2027

Conditions
Advanced Solid TumorLymphoma
Interventions
DRUG

T-1301 Capsules

T-1301 Capsules, 10 and 50 mg, are opaque hard gelatin capsules for oral administration.

Trial Locations (3)

Unknown

RECRUITING

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

RECRUITING

Taipei Veterans General Hospital, Taipei

RECRUITING

ChangGung Memorial Hospital, Linkou, Taoyuan

All Listed Sponsors
lead

Taivex Therapeutics Corporation

INDUSTRY